<DOC>
	<DOCNO>NCT02481856</DOCNO>
	<brief_summary>The trial phase II , randomise , parallel-group , double-blind , placebo-controlled multi-site trial conduct Canada . Before start treatment , subject undergo baseline birch oak Environmental Exposure Chamber session . The treatment duration 24 week . The subject undergo birch Environmental Exposure Chamber session 8 , 16 24 week treatment oak Environmental Exposure Chamber session 24 week treatment .</brief_summary>
	<brief_title>A Dose-response Evaluation SQ Tree SLIT-tablet Using Environmental Exposure Chamber</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Written inform consent obtain trial related procedure perform Male female age 18 65 year Female subject childbearing potential must negative urine pregnancy test willing practise contraceptive method History moderatetosevere rhinoconjunctivitis induce pollen birch group without asthma despite received treatment symptom relieve medication previous 2 tree pollen season Positive SPT response ( wheal diameter ≥ 3 mm ) Betula verrucosa Positive specific IgE Bet v1 ( ≥ IgE Class 2 ; ≥0.70 kU/L ) Willing able comply trial protocol Minimum level rhinoconjunctivitis symptom , define TSS least 7 ( 18 ) , one timepoint birch baseline EEC session . Symptoms induce interfere allergen expect present period subject attends EEC session Rhinoconjunctivitis cause animal hair dander subject regularly expose . Allergic symptom induce perennial allergen house dust mite , mould A clinical history uncontrolled asthma within 3 month prior screen Reduced lung function FEV1 ( &lt; 70 % predict value adequate pharmacological treatment ) Asthma require treatment inhale corticosteroid within past 3 month prior screen Previous treatment allergy immunotherapy product tree pollen allergens crossreacting allergen within past 5 year Ongoing treatment allergy immunotherapy product Immunosuppressive treatment within 3 month prior screen visit Treatment tricyclic antidepressant , catecholamineOmethyltransferase inhibitor , mono amine oxidase inhibitor betablockers Treatment antidepressant medication antihistaminic effect Treatment antipsychotic medication antihistaminic effect Treatment antiIgE drug within 130 days/5 halflives drug ( ever long ) Treatment investigational drug within 30 days/5 halflives drug ( ever long ) prior screen Severe oral inflammation oral wound randomisation Symptoms treatment upper respiratory tract infection , acute sinusitis , acute otitis medium relevant infection resolve 1week prior baseline birch oak Environmental Exposure Chamber session randomisation visit Clinically relevant nasal polyps A history paranasal sinus surgery A history surgery nasal turbinates A history anaphylaxis cardiorespiratory symptom A history recurrent ( define two episode ) generalise urticaria last 2 year A history druginduced ( incl . Allergy Immunotherapy ) facial angioedema family ( parent sibling ) history hereditary angioedema Any clinically relevant chronic disease ( ≥3 month duration ) opinion investigator would interfere trial assessment safety subject An uncontrolled systemic disease affect immune system ( e.g . insulindependent diabetes , autoimmune disease , immune complex disease , immune deficiency disease whether acquire ) A history allergy , hypersensitivity intolerance investigational medicinal product ( except Betula verrucosa ) symptomatic medication provide trial Being immediate family investigator trial staff , define investigator's/staff 's spouse , parent , child , grandparent grandchild .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>